You have 9 free searches left this month | for more free features.

Lymphoma, B-Cell, Marginal Zone

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)

Not yet recruiting
  • OR Regimen Refractory Marginal Zone Lymphoma
  • obrutinib, rituximab
  • (no location specified)
Nov 12, 2023

Marginal Zone Lymphoma Trial (Mosunetuzumab + Lenalidomide, - Rituximab + Lenalidomide (28-days cycles, - Rituximab +

Not yet recruiting
  • Marginal Zone Lymphoma
  • Mosunetuzumab + Lenalidomide
  • +3 more
  • (no location specified)
Aug 16, 2023

Lymphoma Trial (Ultra Low Dose 4 Gy Radiation)

Not yet recruiting
  • Lymphoma
  • Ultra Low Dose 4 Gy Radiation
  • (no location specified)
Jun 30, 2023

Marginal Zone Lymphoma Trial in Tianjin (Obinutuzumab, lenalidomide)

Recruiting
  • Marginal Zone Lymphoma
  • Obinutuzumab, lenalidomide
  • Tianjin, Tian, China
    Institute of Hematology & Blood Diseases Hospital
Apr 27, 2023

Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)

Not yet recruiting
  • Follicular Lymphoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Mar 13, 2023

Molecular Taxonomy of Nodal Marginal Zone Lymphoma

Not yet recruiting
  • Nodal Marginal Zone Lymphoma
    • Paris, France
    • +2 more
    Jan 17, 2023

    Marginal Zone Lymphoma Trial ([68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose)

    Not yet recruiting
    • Marginal Zone Lymphoma
    • (no location specified)
    Nov 6, 2023

    Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

    Recruiting
    • Follicular Lymphoma
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)

    Not yet recruiting
    • Relapsed Non-Hodgkin Lymphoma
    • +6 more
    • (no location specified)
    Apr 12, 2023

    Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,

    Recruiting
    • Relapsed/Refractory Follicular Lymphoma
    • Marginal Zone Lymphoma (MZL)
    • Chiang Mai, Thailand
      Chiang Mai University
    Nov 20, 2023

    Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)

    Active, not recruiting
    • Indolent Non-hodgkin Lymphoma
    • Shanghai, China
      Ruijin hospital, school of medicine, Shanghai jiao tong universi
    Oct 3, 2022

    B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

    Recruiting
    • B-cell Lymphoma
    • +5 more
    • Louisville, Kentucky
      Norton Cancer Institute
    Jan 24, 2023

    Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker

    Active, not recruiting
    • Follicular Lymphoma
    • +2 more
    • Laboratory Biomarker Analysis
    • Pembrolizumab
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 6, 2022

    Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)

    Recruiting
    • Relapsed/Refractory Follicular Lymphoma
    • Marginal Zone Lymphoma
    • Westbury, New York
      Clinical Research Alliance, Inc.
    Nov 14, 2022

    Splenic Marginal Zone Lymphoma Trial in Worldwide (Rituximab, Zanubrutinib)

    Not yet recruiting
    • Splenic Marginal Zone Lymphoma
    • Aarhus, Denmark
    • +4 more
    Feb 17, 2023

    Lymphoma Trial in Milan (clarithromycin, oral, high dose)

    Completed
    • Lymphoma
    • clarithromycin, oral, high dose
    • Milan, Italy
      Dpt of OncoHematology - Fondazione Centro San Raffaele del Monte
    Aug 10, 2022

    Marginal Zone Lymphoma Trial in Miami (Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg)

    Recruiting
    • Marginal Zone Lymphoma
    • Loncastuximab tesirine 150 µg/Kg
    • Loncastuximab tesirine 75µg/Kg
    • Miami, Florida
      University of Miami
    Jul 12, 2022

    Primary Ocular Adnexal MALT Lymphoma Trial (Rituximab, Involved Site Radiation Therapy)

    Not yet recruiting
    • Primary Ocular Adnexal MALT Lymphoma
    • (no location specified)
    Sep 26, 2023

    Relapsed/Refractory Marginal Zone Lymphoma Trial in China (Orelabrutinib, Lenalidomide, Rituximab)

    Not yet recruiting
    • Relapsed/Refractory Marginal Zone Lymphoma
    • Guangzhou, Guangdong, China
    • +10 more
    Oct 8, 2023

    Marginal Zone Lymphoma of Ocular Adnexal Trial in Italy (Doxycycline)

    Active, not recruiting
    • Marginal Zone Lymphoma of Ocular Adnexal
    • Messina, Italy
    • +6 more
    Nov 4, 2022

    Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) Trial (parsaclisib, rituximab, obinutuzumab)

    Withdrawn
    • Follicular Lymphoma ( FL)
    • Marginal Zone Lymphoma (MZL)
    • (no location specified)
    Jul 14, 2022

    Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in Miami (Acalabrutinib,

    Terminated
    • Diffuse Large B Cell Lymphoma
    • +3 more
    • Miami, Florida
      University of Miami
    Aug 23, 2022

    Marginal Zone Lymphoma, Follicular Lymphoma Trial in Aurora (Ublituximab, Umbralisib)

    Suspended
    • Marginal Zone Lymphoma
    • Follicular Lymphoma
    • Aurora, Colorado
      University of Colorado Hospital
    Feb 22, 2022

    Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

    Completed
    • Grade 3a Follicular Lymphoma
    • +9 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 31, 2023